EUTOS - The European Treatment Outcome Study
EUTOS.
EUTOS.
New Research Gives Additional Therapeutic Tools For Even More Effective And Longer Control Of Chronic Myeloid Leukemia
Main Category: Lymphoma / Leukemia
Article Date: 25 Mar 2008
Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML). The results of their study will be published the week of March 24th in the Proceedings of the National Academy of Sciences.
Update on the situation regarding NICE approval of dasatinib (Sprycel) and nilotinib (Tasigna).
02/06/2008
Elias Jabbour; Jorge E Cortes; Hady Ghanem; Susan O'Brien; Hagop M Kantarjian
Abstract
Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.
From The Medscape Journal of Medicine
Webcast Video Editorials
ePatients: Engaging Patients in Their Own Care
Posted 01/25/2008
Daniel Z. Sands, MD, MPH
New Therapeutic Options in CML and What They Mean for Patients:
An Expert Interview With Dr. Jorge Cortes
BMS Press Release:
Uxbridge, UK. January 21, 2008:
Summary:
Imatinib, or Glivec (Gleevec-USA), is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance.
The study findings strengthen the hypothesis that domestic use of pesticides may play a role in the etiology of childhood hematopoietic malignancies. The consistency of the findings with those of previous studies on AL raises the question of the advisability of preventing pesticide use by pregnant women.
ChemGenex Investigators Report Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients with the T315I Mutation